The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Medical device company PolyNovo (PNV) has appointed Dr Joshua Cheetam as Director of Research and Development
  • Joshua has over 25 years of experience in research and development, commercialisation of medical products and manufacturing operations
  • He will focus on quickly growing a research and development team to capture and commercialise the many business developments and new product opportunities
  • On the market close for the weekend, Polynovo is down 2.46 per cent, trading at $2.78 per share

PolyNovo (PNV) has appointed Dr Joshua Cheetam as Director of Research and Development.

Joshua has over 25 years of experience in research and development, commercialisation of medical products and manufacturing operations.

Previously, he has worked as product development manager, operations director, research and development director and Chief Technology Officer at SDI, a medical devices company that specialises in manufacturing dental materials.

Joshua will focus on quickly growing a research and development team to
capture and commercialise the many business developments and new product opportunities.

His role is to lead the innovation strategy and research and development activities and to develop the future product portfolio for PolyNovo.

“This is a very exciting and significant appointment that will spearhead the
building of a world-class research and development team befitting the company’s market capitalisation,” Chairman David Williams said.

Managing Director Paul Brennan says the company will continue to invest in the expansion of its research and development team.

“Joshua will be recruiting additional scientists to bolster the team and accelerate our pipeline of new products,” he added.

On the market close for the weekend, Polynovo is down 2.46 per cent, trading at $2.78 per share.

PNV by the numbers
More From The Market Online

Universal Biosensors surges 60% on FDA approval for Class II device

Universal Biosensors shares surged 60% following the attainment of US Food and Drug Administration and Clinical…

Vitura joint venture prescribes shrooms for therapeutic use in Australian-first

In an Australian-first pharmaceutical achievement, Vitura Health Limited has announced the first ever shipment of 'shrooms'…

Mesoblast (ASX:MSB) completes $97M funding round heading into Q2

Mesoblast (ASX:MSB) has completed its pro-rata accelerated non-renounceable entitlement offer, launched on December 4, 2023.

Recce Pharma (ASX:RCE) kicks-off dosing for next cohort of UTI trial

Recce Pharmaceuticals (ASX: RCE) has announced the successful dosing of the latest group of human participants…